Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
about
BRCAness: finding the Achilles heel in ovarian cancerProteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerCytotoxic and targeted therapy for hereditary cancersCancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromesHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsComparative meta-analysis of prognostic gene signatures for late-stage ovarian cancerThe role of PARP in DNA repair and its therapeutic exploitationPARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesThe `dnet’ approach promotes emerging research on cancer patient survivalUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicUpdate on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentIntegrating cancer genomic data into electronic health recordsPatient-derived tumour xenografts for breast cancer drug discoveryPALB2: the hub of a network of tumor suppressors involved in DNA damage responsesPeptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domainRAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombinationPARP inhibitor treatment in ovarian and breast cancerThe relative efficiency of homology-directed repair has distinct effects on proper anaphase chromosome separation.curatedOvarianData: clinically annotated data for the ovarian cancer transcriptomeMás-o-menos: a simple sign averaging method for discrimination in genomic data analysis.Bayesian clinical classification from high-dimensional data: Signatures versus variability.Pathway-Informed Classification System (PICS) for Cancer Analysis Using Gene Expression Data.Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium reportPCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithmA BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer.Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapyMolecular genetics complexity impeding research progress in breast and ovarian cancers.Investigational agents in development for the treatment of ovarian cancerMicroarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancerPrognostic biomarkers in ovarian cancer.BRCAness profile of sporadic ovarian cancer predicts disease recurrence.PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
P2860
Q24630872-FD088763-F1F2-4CEF-AFF5-3050B7287EB2Q24632628-BF77B0BA-4D05-4F09-921D-1AEDEB231E7FQ26739366-FBE64C04-E976-49A1-91BA-158DE8C2932DQ26776258-4491885E-2AC3-4B91-8D25-DFD66E7824C2Q26783551-FCAF7D35-4C7E-4F07-9436-22C8FEDB2647Q26852274-E0BAB198-44AF-4F12-86F7-47BDC0A1C49DQ26859166-F5077F18-9D83-48D8-8166-E53082D07B92Q27002399-1FFE8B81-2FE7-41F8-A3D4-3BF7AC23E07BQ27027503-91437AD6-6063-4268-8B2B-1C5F146BAC0BQ27499832-5737928B-E4ED-4D3D-B00A-E6723AF5DE8EQ28071541-634C772E-D06E-49C6-BB30-4929AAA0ED4EQ28075761-5A695E4E-0FDB-437E-AF76-483F99EE8A5FQ28077310-8B18CCC1-603C-47F4-8606-149EFF041744Q28080046-98FB3411-5C61-4112-BE04-B06613B59B38Q28243398-54FB5B8E-5B9A-4743-9D4B-F47D3D57FFDDQ28256541-8B731550-2E98-4EBE-8D6C-2975BC666DEAQ28274789-7F5F2007-A335-41E4-899D-ED87D92F9668Q28741688-DF6643E1-E1DF-4B75-95BB-A5F74F07C06CQ30503322-F658F64A-D69C-4263-B493-E5511285F792Q30611147-8A2D344B-117F-42AA-A444-85680655E8B3Q30838620-40301E36-922C-4420-9569-0332C10B83E8Q31059415-368CBC62-58E9-44A6-9E94-B8A11FC779F0Q31119292-590FFC56-628C-4E4D-BC5F-F8D8159B743AQ33415400-FBB3D979-3E2E-4976-9FEA-0028713678D2Q33415790-860E1B96-ED46-48D6-8DED-BC703FB9E5D6Q33565650-FD824E15-0EB1-47F5-A214-BCFD97790687Q33731278-1FE39080-595B-49BA-A7FE-6B65F4BAEFB9Q33739161-B1886453-EE9D-4DC4-9DAE-DFC71E00F6B9Q33750060-74AC5F96-DCB4-448E-A252-582CFAB9DAE4Q33757073-3E256D35-2656-48F4-BBF5-9CAFDCE6C6E8Q33762042-C28D1102-D621-4FC6-B1BB-C17D3E2DB606Q33798999-34925035-4156-46B9-AD57-7966B3C31B1CQ33827045-B294DAC8-FC4A-4CAA-915C-C5694604AAA7Q33858073-DF611438-3CC1-4674-8D61-6C83158C1037Q33920800-57C28EB7-E726-4641-83EC-08CA2B73D2BAQ33974923-9D2EB86D-4054-4E7C-8A8B-81D7656C63C8Q34060699-CAF3B109-0A7D-428C-A522-84DC3AC49025Q34086636-3DB308FB-1159-4859-9802-51B586D7AC10Q34130956-D2A1205B-19A3-4BC6-8D83-5274A5494F1EQ34215904-7D4167D2-CD4F-40A6-BF17-4C4061B3260E
P2860
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Gene expression profile of BRC ...... ith epithelial ovarian cancer.
@ast
Gene expression profile of BRC ...... ith epithelial ovarian cancer.
@en
Gene expression profile of BRC ...... ith epithelial ovarian cancer.
@nl
type
label
Gene expression profile of BRC ...... ith epithelial ovarian cancer.
@ast
Gene expression profile of BRC ...... ith epithelial ovarian cancer.
@en
Gene expression profile of BRC ...... ith epithelial ovarian cancer.
@nl
prefLabel
Gene expression profile of BRC ...... ith epithelial ovarian cancer.
@ast
Gene expression profile of BRC ...... ith epithelial ovarian cancer.
@en
Gene expression profile of BRC ...... ith epithelial ovarian cancer.
@nl
P2093
P2860
P921
P356
P1476
Gene expression profile of BRC ...... with epithelial ovarian cancer
@en
P2093
Beth Y Karlan
Dimitrios Spentzos
Douglas A Levine
Elena Fountzilas
Nancy Francoeur
Panagiotis A Konstantinopoulos
Stephen A Cannistra
P2860
P304
P356
10.1200/JCO.2009.27.5719
P407
P577
2010-06-14T00:00:00Z